A first-in-human, gene-silencing treatment for Alzheimer’s disease with Catherine Mummery

Video Journal of Biomedicine | Expert Perspective

In this video, Catherine Mummery of University College London, UK discusses the newly commenced Neurogenetic Therapies Programme that aims to build on advances in understanding the genetic basis of neurodegenerative diseases, and significantly speed up their translation into effective treatments. Catherine also presents an overview of gene-silencing treatment, providing her perspective on the challenges with this novel treatment approach, how these can be overcome and her thoughts on how she foresees the field will progress over the next 10 years.

About the author:

Cath Mummery is a consultant neurologist and leads the Cognitive Disorders Service at the National Hospital for Neurology and Neurosurgery. She is Head of Novel Therapeutics at the Dementia Research Centre, UCL and has been senior investigator on over 20 early phase drug trials of disease modifying agents, including immunotherapy in presymptomatic individuals at risk of familial AD, and first-in-human phase I antisense oligonucleotide study, reducing tau accumulation in AD. She is Deputy Director for the Leonard Wolfson Experimental Neurology Centre at NHNN, a unit dedicated to early phase trials in neurodegeneration.

Original publication:

Video originally published on Neuro Central, a digital platform from the Future Science Group that unites all aspects of neurology and neuroscience.